Trial reportDrug and alcohol dependence2011
Separate and combined effects of the cannabinoid agonists nabilone and Δ⁹-THC in humans discriminating Δ⁹-THC.
Trial report in Drug and alcohol dependence, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 33 citations in OpenAlex.
- Medical cannabinoids: a pharmacology-based systematic review and meta-analysis for all relevant medical indications.BMC medicine · 2022Pooled it
- Evaluating the Abuse Potential of Lenabasum, a Selective Cannabinoid Receptor 2 Agonist.The Journal of pharmacology and experimental therapeutics · 2024Trial
- Nabilone pharmacotherapy for cannabis dependence: A randomized, controlled pilot study.The American journal on addictions · 2017Trial
- Effects of zolpidem alone and in combination with nabilone on cannabis withdrawal and a laboratory model of relapse in cannabis users.Psychopharmacology · 2016Trial
- Subjective, cognitive and cardiovascular dose-effect profile of nabilone and dronabinol in marijuana smokers.Addiction biology · 2013Trial
- Article
- How do phytocannabinoids affect cardiovascular health? An update on the most common cardiovascular diseases.Therapeutic advances in chronic disease · 2023Review
- Effects of repeated adolescent exposure to cannabis smoke on cognitive outcomes in adulthood.Journal of psychopharmacology (Oxford, England) · 2021Article
- Evidence for the Endocannabinoid System as a Therapeutic Target in the Treatment of Cannabis Use Disorder.Current addiction reports · 2020Article
- Sex differences in the subjective effects of oral ΔPharmacology, biochemistry, and behavior · 2017Article
- Separate and combined effects of the GABAA positive allosteric modulator diazepam and Δ⁹-THC in humans discriminating Δ⁹-THC.Drug and alcohol dependence · 2014Article
- "Herbal incense": designer drug blends as cannabimimetics and their assessment by drug discrimination and other in vivo bioassays.Life sciences · 2014Review
- Nabilone decreases marijuana withdrawal and a laboratory measure of marijuana relapse.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2013Article
- Separate and combined effects of the GABA(B) agonist baclofen and Δ9-THC in humans discriminating Δ9-THC.Drug and alcohol dependence · 2012Article
- Triphasic blood pressure responses to cannabinoids: do we understand the mechanism?British journal of pharmacology · 2012Review
- Separate and combined effects of the GABA reuptake inhibitor tiagabine and Δ9-THC in humans discriminating Δ9-THC.Drug and alcohol dependence · 2012Article
- AM2389, a high-affinity, in vivo potent CB1-receptor-selective cannabinergic ligand as evidenced by drug discrimination in rats and hypothermia testing in mice.Psychopharmacology · 2012Article
- Physiological and subjective effects of acute intranasal methamphetamine during extended-release alprazolam maintenance.Drug and alcohol dependence · 2011Article
- Human Drug Discrimination: Elucidating the Neuropharmacology of Commonly Abused Illicit Drugs.Current topics in behavioral neurosciencesReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundAgonist replacement treatment is a promising strategy to manage cannabis-use disorders. The aim of this study was to assess the combined effects of the synthetic cannabinoid agonist nabilone and Δ⁹-tetrahydrocannabinol (Δ⁹-THC) using drug-discrimination procedures, which are sensitive to drug interactions. Testing the concurrent administration of nabilone and Δ⁹-THC was also conducted to provide initial safety and tolerability data, which is important because cannabis users will likely lapse during treatment.
methodsSix cannabis users learned to discriminate 30 mg oral Δ⁹-THC from placebo and then received nabilone (0, 1 and 3mg) and Δ⁹-THC (0, 5, 15 and 30 mg), alone and in combination. Subjects completed the multiple-choice procedure to assess drug reinforcement, and self-report, task performance and physiological measures were collected.
resultsΔ⁹-THC and nabilone alone shared discriminative-stimulus effects with the training dose of Δ⁹-THC, increased crossover point on the multiple-choice procedure, produced overlapping subject ratings and decreased skin temperature. Nabilone alone also elevated heart rate. In combination, nabilone shifted the discriminative-stimulus effects of Δ⁹-THC leftward/upward and enhanced Δ⁹-THC effects on the other outcome measures.
conclusionsThese results replicate a previous study demonstrating that nabilone shares agonist effects with the active constituent of cannabis in cannabis users, and contribute further by indicating that nabilone would likely be safe and well tolerated when combined with cannabis. These data support the conduct of future studies to determine if nabilone treatment would produce cross-tolerance to the abuse-related effects of cannabis and reduce cannabis use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.